08/17 Taiwan BIO Weekly
2026-08-17 |
| Taiwan BIO Weekly |
| Taiwan could host more clinical trials 16 August, 2026 Taiwan should capitalize on its strengths in Phase 1 and Phase 2 clinical trials and strive to overtake competitors, with the goal of establishing Taiwan as an "Asia-Pacific center for innovative treatments for rare diseases," said Minister of Health and Welfare Shih Chung-liang yesterday. He made the remark while promoting the Regenerative Medicine Act and aligning with international standards in a forum titled "From Innovation to IPO: Redefining Global Healthcare Capital" in Taipei. More... |
| Adimmune's Benova Bio Secures First Swine Bivalent Vaccine License, Targeting US$1 Billion Asian Market Press release 14 August, 2026 Adimmune Corporation (TW: 4142) has officially entered the animal vaccine market. Its subsidiary, Benova Bio, announced on the 11th that a bivalent vaccine targeting Porcine Circovirus (PCV) recombinant and Mycoplasma hyopneumoniae (SEP), co-developed with Taiwan's Agricultural Technology Research Institute, received an animal vaccine license from Taiwan's Ministry of Agriculture at the end of July. This marks the Adimmune group's first animal vaccine license, officially targeting the swine vaccine opportunity in Taiwan and Southeast Asia, valued at up to US$1 billion annually (approximately NT$32 billion). More... |
| TAHO Pharmaceuticals' CDO Strategy Begins to Bear Fruit 13 August, 2026 TAHO Pharmaceuticals (TW: 6467) said it recognized revenue from CDO projects for the second consecutive month in July, with monthly revenue rising from NT$1.318 million in June to NT$1.671 million in July, reflecting growing contributions from its expanding CDO business. The company has completed dosage-form development projects for two US biotech companies, while an ongoing project for a multinational pharmaceutical company has also begun generating revenue. More... (in Chinese) |
| Belite Bio's Stargardt Eye Drug Application Accepted by US FDA, Decision Expected in February 12 August, 2026 Belite Bio, a subsidiary of Taiwan's Lin Bioscience (TW: 6696), announced on the 12th of August that the US FDA has accepted its New Drug Application (NDA) for oral drug Tinlarebant (LBS-008) for the treatment of Stargardt disease (STGD1) and granted it Priority Review designation. Under the Prescription Drug User Fee Act (PDUFA), the US FDA has set a target action date of February 12, 2027. If approved, Tinlarebant could become the worldÕs first approved treatment for STGD1. More... (in Chinese) |
| PharmaEssentia's first-half profit surges 120% YoY, EPS reaches NT$11.35, gross margin hits 91% 12 August, 2026 PharmaEssentia (TW: 6446) reported first-half 2026 net profit of NT$4.679 billion, up 123% year over year, with EPS of NT$11.35. The company said profitability increased significantly in the first half. Its main product, Ropeg, is currently approved for polycythemia vera (PV), and the company is targeting approval for essential thrombocythemia (ET) by the end of August 2026. More... (in Chinese) |
| TaiGen Biotechnology's influenza drug approved for Phase III clinical trial in South Korea 11 August, 2026 TaiGen Biotechnology (TW: 4157) announced that South Korea's Ministry of Food and Drug Safety (MFDS) has approved the IND application for a Phase III clinical trial of the influenza drug Pixavir marboxil (BRC-201) oral capsules. The approval was obtained by TaiGen's South Korean partner, Boryung Biopharma, which will conduct the trial and continue development activities in South Korea. TaiGen and Boryung signed a licensing agreement in January 2026 granting Boryung development and commercialization rights for Pixavir marboxil in the South Korean market. More... (in Chinese) |
| Foresee Pharmaceuticals' July Revenue Surges 242% YoY as CAMCEVI Commercialization Gains Momentum 11 August, 2026 Foresee Pharmaceuticals (TW: 6576) reported July 2026 consolidated revenue of approximately NT$30.28 million, up 177% month over month and 242% year over year. First seven-month revenue reached NT$292 million, up 26.5% year over year. July revenue included NT$22.45 million from US sales of six-month CAMCEVI, NT$6.12 million in US and European sales royalties, and NT$1.71 million in service revenue. Its licensing partner plans to launch the three-month CAMCEVI formulation in the US and Europe in the second half of 2026. Foresee also plans to file a US NDA for FP-001 42 mg for central precocious puberty in the second half of 2026, targeting an in-house US launch in the second half of 2027. More... |
| Taiwan Biobank planning next research phase 11 August, 2026 The Taiwan Biobank, building upon its database of genotype data from 200,000 peoples, is to launch its next phase -- large-scale plasma proteomic testing, Academia Sinica President Chen Chien-jen said yesterday. Large-scale plasma proteomic testing, integrated with multiomics analysis and international research, is expected to give East Asian populations a more prominent place on the global proteogenomic map, Chen said. More... |
| EirGenix's July revenue and cumulative revenue for the first seven months both hit three-year highs 10 August, 2026 EirGenix (TW: 6589) announced that both July revenue and cumulative revenue for the first seven months of 2026 had reached three-year highs. July revenue exceeded NT$200 million, representing a 184% increase year over year, while cumulative revenue for January-July reached NT$833 million, up 71% from the same period last year. The revenue growth was mainly driven by the steady expansion of its CDMO (contract development and manufacturing) business, as well as the recognition of milestone payments related to two HER2 biosimilars, EG12014 and EG1206A, for the global and Japanese markets, which significantly boosted overall revenue. More... (in Chinese) |
| 2026 Cancer Summit: Advancing "Healthy Taiwan" Through Strategic Investment 10 August, 2026 The Regent Taipei served as the venue for the 2026 Cancer Summit, jointly convened by the American Chamber of Commerce in Taiwan (AmCham Taiwan) and the American Institute in Taiwan (AIT). The event's main theme was "Advancing 'Healthy Taiwan': Setting Global Benchmarks through Strategic Investment." It brought together key figures from across government agencies, healthcare management, academic institutions, and patient groups. More... |
| Oncology's Next Challenge IsnÕt Innovation--ItÕs Delivery 9 August, 2026 After two decades of rapid scientific breakthroughs--from immunotherapies and targeted medicines to antibody-drug conjugates (ADCs)--oncology is entering a new phase. The challenge is no longer simply developing innovative cancer treatments, but ensuring healthcare systems can deliver them sustainably and equitably through timely diagnostics, reimbursement, and patient access. "Cancer isn't a death sentence anymore--or it doesn't have to be," said Tina Graves, Vice President and General Manager of GSK Taiwan. More... |
| HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology Press release 9 August, 2026 HanchorBio, Inc. (TW: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that its wholly owned Taiwan subsidiary has entered into a strategic collaboration with the research team led by Professor Sung-Liang Yu of National Taiwan University, a key participating team in the Taiwan Cancer Moonshot Program (TCMP). The collaboration has been formalized through a memorandum of understanding signed by HanchorBio Taiwan and Professor Yu's team. More... |
| TAITRA highlights Taiwan's competitive edge in AI healthcare 8 August, 2026 Taiwan External Trade Development Council (TAITRA) Chairman James C. F. Huang said this Wednesday at the 2026 Global AI Health Tech Forum that Taiwan is uniquely positioned to have a competitive advantage in AI and smart healthcare applications. The forum, held in Taipei, was organized by TAITRA and designed to introduce the latest international AI healthcare knowledge and technology. More... |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= Taiwan BIO is not responsible for the accuracy of the contents of news articles linked. |